Fludarabine Phosphate: clinical trials recruiting now
FDA drug label
- FDA-approved
- Yes. Fludarabine Phosphate appears in the FDA drug-label database. Marketed as Fludarabine Phosphate.
- Boxed warning
- The FDA label for Fludarabine Phosphate carries a boxed warning (the FDA's most serious warning). See the full label for details.
FDA-approved use
Fludarabine Phosphate Injection is a nucleotide metabolic inhibitor indicated for: The treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen. Benefit in treatment-naïve or non-refractory CLL patients is not established. ( 1.1 ) 1.1 Indication Fludarabine Phosphate Injection is indicated for the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen. The safety and effectiveness of Fludarabine Phosphate Injection in previously untreated or non-refractory patients with CLL have not been established.
Phase breakdown
Conditions being studied
Recruiting trials involving Fludarabine Phosphate
- Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
- Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
- To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma
Common questions
Is Fludarabine Phosphate FDA-approved?
Yes, marketed as Fludarabine Phosphate. Its FDA label carries a boxed warning.
How many recruiting trials involve Fludarabine Phosphate?
3 recruiting trials across 15 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.